Palvella Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Palvella Therapeutics (PVLA) with an Overweight rating and $30 price target The quality of companies pursuing reverse mergers has improved considerably lately and now represent an opportunity to find “hidden gems” such as Palvella, the analyst tells investors in a research note. Palvella recently initiated a Phase 3 single-arm, baseline controlled study evaluating daily QTORIN rapamycin in microcystic Lymphatic Malformations, and Cantor remains optimistic in the company’s ability to push this past the finish line.